Skip to Content

Nivolumab + Cabozantinib Remains Standard of Care in First-Line Treatment for Advanced Renal Cell Carcinoma

This 55-month median follow-up of the CheckMate 9ER study on efficacy in the intention-to-treat population reinforces nivolumab plus cabozantinib as standard first-line therapy for advanced renal cell carcinoma.

Get access

If you are a doctor, nurse, or other health professionals, you can access the entire article by creating a profile on BestPractice Nordic.

Back to top